Exactly. Trading on December 17th indicated nothi
Post# of 148292
Speaking of bets. Anyone think it's odd that enrollment in the mild/mod trial seemed to stall at 45 patients (a round 2:1 number) for roughly two weeks (endpoint time frame), and now we have an unexpected and vague conference call regarding clinical updates and regulatory developments? NP has hinted plenty that the FDA may be able to look at the data early. Not saying I'm banking on anything, but I do think that those are interesting coincidences.